The inhalation of the non-psychoactive cannabinoid CBD (cannabidiol) significantly mitigates tobacco smokers’ desire for cigarettes, according to clinical trial data published online in the journal Addictive Behaviors. Investigators concluded, “This is the first study, as far as we are aware, to demonstrate the impact of CBD on cigarette smoking. … These preliminary data, combined with the strong preclinical rationale for use of this compound, suggest CBD to be a potential treatment for nicotine addiction that warrants further exploration.”
Preclinical study data published online in the scientific journal Nutrition & Diabetes reports that tetrahydrocannabivarin (THCV) — a naturally occurring analogue of THC — possesses positive metabolic effects in animal models of obesity. Researchers concluded: “Based on these data, it can be suggested that THCV may be useful for the treatment of the metabolic syndrome and/or type 2 diabetes (adult onset diabetes), either alone or in combination with existing treatments.”
Recent preclinical studies published over the past weeks provide further evidence that cannabinoids are both neuroprotective and cardioprotective.
The consumption of legal hemp seed nutritional oil, in conjunction with the intake of evening primrose oils and a restrictive diet high in Hot-natured foods (such as pepper) and low in saturated fats and sugars, is associated with “significant improvement” in symptom management and immunological characteristics in subjects with multiple sclerosis, according to clinical trial data published this month in the scientific journal BioImpacts.
Adults with a history of marijuana use have a lower prevalence of type 2 diabetes and possess a lower risk of contracting the disease than those with no history of cannabis consumption, according to clinical trial data published in the British Medical Journal. Investigators at the University of California, Los Angeles assessed the association between diabetes mellitus (DM) and marijuana use among adults aged 20 to 59 in a nationally representative sample of the US population of 10,896 adults. The study included four groups: non-marijuana users (61.0%), past marijuana users […]
The oral administration of the non-psychotropic cannabis plant constituent cannabidiol (CBD) is safe and well tolerated in humans, according to clinical trial data published online by the journal Current Pharmaceutical Design. Investigators at Kings College in London assessed the physiological and behavioral effects of CBD and THC versus placebo in 16 healthy volunteers in a randomized, double-blind, crossover trial. Investigators reported that the oral administration of 10 mg of THC was associated with various physiological and behavioral effects – such as increased heart rate and sedation – whereas the oral […]
The combined administration of the plant cannabinoids THC and CBD (cannabidiol) provide neuroprotection in rat models of Huntington’s Disease (HD), according to experimental data to be published in the Journal of Neuroscience Research.
Huntington’s Disease is an inherited degenerative brain disorder characterized by motor abnormalities and dementia produced by selective lesions in the cerebral cortex and, […]
By Fred Gardner
Project CBD has just sent out its introductory pitch to California dispensaries. ProjectCBD.org is the medical marijuana movement living up to its name,” explains outreach coordinator Sarah Russo, optimistically, as she asks the dispensaries to participate in a “collective research effort.” But what are the chances that the dispensary owners, intent on building […]